Jonathan Aschoff
Stock Analyst at Roth MKM
(0.81)
# 3,249
Out of 4,666 analysts
45
Total ratings
26.83%
Success rate
-24.36%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.97 | +134.11% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $15 → $8 | $0.29 | +2,658.62% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.40 | +1,185.71% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $17 | $1.30 | +1,207.69% | 2 | Aug 13, 2024 | |
| OTRK Ontrak | Maintains: Buy | $60 → $45 | $1.83 | +2,359.02% | 2 | Aug 9, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $2.61 | +666.28% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $21 → $11 | $0.37 | +2,862.56% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $2.67 | +1,398.13% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $20 → $28 | $1.56 | +1,694.87% | 4 | Mar 28, 2024 | |
| TFFP TFF Pharmaceuticals | Maintains: Buy | $56 → $44 | $0.37 | +11,718.43% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $40 | $0.79 | +4,978.08% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $7.52 | +378.72% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $24 | $0.45 | +5,207.39% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $4.77 | +528.93% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $4.09 | +4,789.98% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $1.82 | +669.23% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $450 | $0.76 | +59,204.16% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $0.92 | +770.99% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.55 | +3,821.57% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.78 | +51,188.63% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $4.41 | +761.68% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $480 | $0.17 | +290,809.09% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $3.97 | +2,318.14% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $4.56 | +185.09% | 1 | Dec 19, 2019 |
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.97
Upside: +134.11%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $15 → $8
Current: $0.29
Upside: +2,658.62%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.40
Upside: +1,185.71%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $17
Current: $1.30
Upside: +1,207.69%
Ontrak
Aug 9, 2024
Maintains: Buy
Price Target: $60 → $45
Current: $1.83
Upside: +2,359.02%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $2.61
Upside: +666.28%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $21 → $11
Current: $0.37
Upside: +2,862.56%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $2.67
Upside: +1,398.13%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $20 → $28
Current: $1.56
Upside: +1,694.87%
TFF Pharmaceuticals
Mar 28, 2024
Maintains: Buy
Price Target: $56 → $44
Current: $0.37
Upside: +11,718.43%
Mar 27, 2024
Maintains: Buy
Price Target: $12 → $40
Current: $0.79
Upside: +4,978.08%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $7.52
Upside: +378.72%
Mar 5, 2024
Maintains: Buy
Price Target: $5 → $24
Current: $0.45
Upside: +5,207.39%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $4.77
Upside: +528.93%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $4.09
Upside: +4,789.98%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $1.82
Upside: +669.23%
Feb 14, 2023
Maintains: Buy
Price Target: $150 → $450
Current: $0.76
Upside: +59,204.16%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $0.92
Upside: +770.99%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.55
Upside: +3,821.57%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.78
Upside: +51,188.63%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $4.41
Upside: +761.68%
Feb 12, 2021
Initiates: Buy
Price Target: $480
Current: $0.17
Upside: +290,809.09%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $3.97
Upside: +2,318.14%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $4.56
Upside: +185.09%